Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial

Clicks: 11
ID: 329246
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #197 of 338 articles by views in american journal of epidemiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 338 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Appropriate use of recently approved type 2 diabetes treatments depends on external validity of landmark clinical trials (RCTs) in real-world populations that may differ from trial participants. This study transported effect estimates from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, a placebo-controlled RCT of liraglutide on cardiovascular outcomes, onto real-world cohorts within the Veterans Affairs (VA) healthcare system. Risk differences (RD) in survival outcomes, approximated using pseudo-observations of individual survival probabilities, were estimated with augmented inverse probability weighting after balancing baseline characteristics between RCT and target samples using approximate balancing weights. Transported effects of liraglutide compared to placebo on major adverse cardiovascular events (MACE) and all-cause mortality in veterans (“VA-weighted LEADER”) were larger than, though statistically consistent with, the treatment effects observed in LEADER: MACE RD at 3 years of 4.6% [95% CI 2.2, 7.0] in VA-weighted LEADER versus 1.6% [0.3, 2.9] in LEADER; all-cause mortality RD at 3 years of 2.9% [0.8, 5.1] in VA-weighted LEADER versus 0.9% [-0.09, 1.9] in LEADER. These estimates of the effects of liraglutide in veterans with diabetes provide real-world evidence that can guide diabetes treatment decisions and formulary policies for a high-risk population underrepresented in RCTs.
Reference Key
openalex_W7213975783 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kevin Josey, Wenhui Liu, Theodore Warsavage, Morten Medici, Kajsa Kvist, Catherine G. Derington, Jane E B Reusch, Debashis Ghosh, Sridharan Raghavan
Journal american journal of epidemiology
Year 2026
DOI
10.1093/aje/kwag236
URL
https://doi.org/10.1093/aje/kwag236
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.